MedTrace Logo

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

NCT06408246 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2026-03-05

No results posted yet for this study

Summary

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.

Conditions

Interventions

DRUG

Guanfacine

Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.

DRUG

Sertraline

Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.

Sponsors & Collaborators

Principal Investigators

  • Leanne Williams, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-03
Primary Completion
2028-10-01
Completion
2029-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408246 on ClinicalTrials.gov